News & Events

Simpson Thacher represented 10x Genomics, Inc. (the “Company”) in its underwritten public offering of 4,600,000 shares of the Company’s Class A common stock, which raised approximately $506 million in gross proceeds, with the Company receiving all of the proceeds from the offering. During the marketing the offering size was upsized from its original target and as part of the offering, the joint book-running managers J.P. Morgan Securities LLC, BofA Securities and Cowen and Company, LLC exercised, in full, their option to purchase additional shares of the Company’s Class A common stock.

10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology.

The Simpson Thacher team included Kevin Kennedy, Adam Spaulding and Jacob Gindt (Capital Markets).